drugset / Trial / NCT05595889
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |